Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Dr Paul Overton becomes Chief Commercial Officer (CCO) at Sygnature

Dr Paul Overton has been named as Sygnature’s first Chief Commercial Officer (CCO) and also takes a position on the board as an Executive Director.

Dr Overton, who joined us in July 2020 following more than 20 years’ experience in business development roles within the CRO sector, formally took the reins this month from Dr Paul Clewlow as Senior Vice President: Business Development.

Sygnature has grown rapidly over recent years, developing organically and by acquisition, and now employs over 425 employees.

The creation of this position for Dr Overton is a reflection of the importance of strong commercial growth to the company’s future strategy, as it continues to develop and deliver integrated drug discovery solutions to the global market.

‘There has been a rapid growth in our customer base, and we see huge potential for partnership with major pharmaceutical and biotech companies,’ says CEO Dr Simon Hirst. ‘Business development is critical to achieving this, and Paul Overton’s experience within larger companies will be extremely helpful to us as we grow.

“Paul will be key in helping us build on our worldwide client base and forge important strategic partnerships with customers. With the increasing complexity of the integrated drug discovery programmes we undertake, his skills in delivering these projects will be invaluable.’

Latest News

View All

Sygnature Discovery and Daewoong Pharma announce research…

New platform set to accelerate early-stage targeted…

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…